RU2587051C2 - Интраназальные фармацевтические дозированные формы, содержащие налоксон - Google Patents

Интраназальные фармацевтические дозированные формы, содержащие налоксон Download PDF

Info

Publication number: RU2587051C2
Authority: RU; Russia
Prior art keywords: naloxone; dosage form; naloxone hcl; nasal; application
Prior art date: 2011-05-13

Application number

RU2013155479/15A

Other languages

English (en)

Russian (ru)

Other versions

RU2013155479A (ru

Inventor

Джон СТРЕНГ

Александер ОКШЕ

Стефен ХАРРИС

Кевин Смит

Люси Элен Жанн МОТЬЕ

Original Assignee

Эро-Селтик С.А.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-13

Filing date

2012-05-11

Publication date

2016-06-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44658496&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2587051(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-05-11 Application filed by Эро-Селтик С.А. filed Critical Эро-Селтик С.А.

2015-06-20 Publication of RU2013155479A publication Critical patent/RU2013155479A/ru

2016-06-10 Application granted granted Critical

2016-06-10 Publication of RU2587051C2 publication Critical patent/RU2587051C2/ru

Links

229960004127 naloxone Drugs 0.000 title claims abstract description 538
239000002552 dosage form Substances 0.000 title claims abstract description 141
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 title claims abstract 29
239000007788 liquid Substances 0.000 claims abstract description 166
150000003839 salts Chemical class 0.000 claims abstract description 52
238000011282 treatment Methods 0.000 claims abstract description 25
208000024891 symptom Diseases 0.000 claims abstract description 19
229940079593 drug Drugs 0.000 claims description 55
239000003814 drug Substances 0.000 claims description 55
229940005483 opioid analgesics Drugs 0.000 claims description 30
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 23
239000007922 nasal spray Substances 0.000 claims description 20
229940097496 nasal spray Drugs 0.000 claims description 20
208000012488 Opiate Overdose Diseases 0.000 claims description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
239000011780 sodium chloride Substances 0.000 claims description 11
238000004448 titration Methods 0.000 claims description 11
238000007918 intramuscular administration Methods 0.000 claims description 8
239000006207 intravenous dosage form Substances 0.000 claims description 8
208000004756 Respiratory Insufficiency Diseases 0.000 claims description 7
206010038678 Respiratory depression Diseases 0.000 claims description 7
239000006204 intramuscular dosage form Substances 0.000 claims description 6
230000002262 irrigation Effects 0.000 claims description 5
238000003973 irrigation Methods 0.000 claims description 5
230000003232 mucoadhesive effect Effects 0.000 claims description 5
238000003780 insertion Methods 0.000 claims description 4
230000037431 insertion Effects 0.000 claims description 4
208000022540 Consciousness disease Diseases 0.000 claims description 3
206010021143 Hypoxia Diseases 0.000 claims description 3
206010035669 Pneumonia aspiration Diseases 0.000 claims description 3
201000009807 aspiration pneumonia Diseases 0.000 claims description 3
208000018875 hypoxemia Diseases 0.000 claims description 3
210000001747 pupil Anatomy 0.000 claims description 3
150000001875 compounds Chemical class 0.000 claims description 2
230000002980 postoperative effect Effects 0.000 claims description 2
230000001154 acute effect Effects 0.000 claims 1
231100000516 lung damage Toxicity 0.000 claims 1
230000009471 action Effects 0.000 abstract description 16
230000000694 effects Effects 0.000 abstract description 12
239000000126 substance Substances 0.000 abstract description 3
RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 description 510
239000013543 active substance Substances 0.000 description 28
238000003379 elimination reaction Methods 0.000 description 19
238000002347 injection Methods 0.000 description 18
239000007924 injection Substances 0.000 description 18
238000001990 intravenous administration Methods 0.000 description 18
239000012530 fluid Substances 0.000 description 14
230000036470 plasma concentration Effects 0.000 description 14
230000008030 elimination Effects 0.000 description 11
238000000034 method Methods 0.000 description 11
210000002381 plasma Anatomy 0.000 description 10
238000012360 testing method Methods 0.000 description 8
241000282412 Homo Species 0.000 description 7
238000010521 absorption reaction Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000007921 spray Substances 0.000 description 7
238000004458 analytical method Methods 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 6
210000001331 nose Anatomy 0.000 description 6
230000001839 systemic circulation Effects 0.000 description 6
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 5
230000002411 adverse Effects 0.000 description 5
230000034994 death Effects 0.000 description 5
231100000517 death Toxicity 0.000 description 5
229960002069 diamorphine Drugs 0.000 description 5
235000019441 ethanol Nutrition 0.000 description 5
238000012216 screening Methods 0.000 description 5
239000003433 contraceptive agent Substances 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000007717 exclusion Effects 0.000 description 4
230000029142 excretion Effects 0.000 description 4
210000000214 mouth Anatomy 0.000 description 4
239000012071 phase Substances 0.000 description 4
238000011160 research Methods 0.000 description 4
206010012335 Dependence Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
208000012266 Needlestick injury Diseases 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000001802 infusion Methods 0.000 description 3
208000014674 injury Diseases 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
239000011591 potassium Substances 0.000 description 3
230000036387 respiratory rate Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
108010082126 Alanine transaminase Proteins 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
102000003840 Opioid Receptors Human genes 0.000 description 2
108090000137 Opioid Receptors Proteins 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
238000008050 Total Bilirubin Reagent Methods 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
206010069351 acute lung injury Diseases 0.000 description 2
-1 alkali metal salts Chemical class 0.000 description 2
238000009534 blood test Methods 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000001680 brushing effect Effects 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000009535 clinical urine test Methods 0.000 description 2
230000002254 contraceptive effect Effects 0.000 description 2
239000006184 cosolvent Substances 0.000 description 2
238000013461 design Methods 0.000 description 2
238000001784 detoxification Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
210000003128 head Anatomy 0.000 description 2
201000011066 hemangioma Diseases 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
229940093267 naloxone 0.7 mg Drugs 0.000 description 2
229940104896 naloxone 1.4 mg Drugs 0.000 description 2
229960005250 naloxone hydrochloride Drugs 0.000 description 2
230000003533 narcotic effect Effects 0.000 description 2
210000003928 nasal cavity Anatomy 0.000 description 2
210000002850 nasal mucosa Anatomy 0.000 description 2
239000000820 nonprescription drug Substances 0.000 description 2
229940127240 opiate Drugs 0.000 description 2
244000052769 pathogen Species 0.000 description 2
231100000915 pathological change Toxicity 0.000 description 2
230000036285 pathological change Effects 0.000 description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000000955 prescription drug Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
238000004088 simulation Methods 0.000 description 2
206010041232 sneezing Diseases 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
150000003892 tartrate salts Chemical class 0.000 description 2
230000036269 ulceration Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
NYNKCGWJPNZJMI-UHFFFAOYSA-N Clebopride malate Chemical compound [O-]C(=O)C(O)CC(O)=O.COC1=CC(N)=C(Cl)C=C1C(=O)NC1CC[NH+](CC=2C=CC=CC=2)CC1 NYNKCGWJPNZJMI-UHFFFAOYSA-N 0.000 description 1
UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
206010012441 Dermatitis bullous Diseases 0.000 description 1
206010015218 Erythema multiforme Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
208000005232 Glossitis Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
208000022120 Jeavons syndrome Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000026251 Opioid-Related disease Diseases 0.000 description 1
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
208000037062 Polyps Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
231100000643 Substance intoxication Toxicity 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
208000025569 Tobacco Use disease Diseases 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000012491 analyte Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
208000002399 aphthous stomatitis Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
230000006399 behavior Effects 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004638 bioanalytical method Methods 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
208000002352 blister Diseases 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
244000078885 bloodborne pathogen Species 0.000 description 1
229960001736 buprenorphine Drugs 0.000 description 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
238000004422 calculation algorithm Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000011970 concomitant therapy Methods 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
229950006073 cotinine Drugs 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
238000005034 decoration Methods 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000035622 drinking Effects 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
208000001780 epistaxis Diseases 0.000 description 1
235000020650 eye health related herbal supplements Nutrition 0.000 description 1
229960002428 fentanyl Drugs 0.000 description 1
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
206010016629 fibroma Diseases 0.000 description 1
DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
229960004039 finasteride Drugs 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
208000014617 hemorrhoid Diseases 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
229960001410 hydromorphone Drugs 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
208000002741 leukoplakia Diseases 0.000 description 1
201000011486 lichen planus Diseases 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
150000004701 malic acid derivatives Chemical class 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
229960001797 methadone Drugs 0.000 description 1
229940029985 mineral supplement Drugs 0.000 description 1
235000020786 mineral supplement Nutrition 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
229940051866 mouthwash Drugs 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
229940100652 nasal gel Drugs 0.000 description 1
210000000492 nasalseptum Anatomy 0.000 description 1
230000008693 nausea Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000003401 opiate antagonist Substances 0.000 description 1
201000005040 opiate dependence Diseases 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
229960002085 oxycodone Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
208000015768 polyposis Diseases 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011867 re-evaluation Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000009589 serological test Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000000934 spermatocidal agent Substances 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000008733 trauma Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000004034 viscosity adjusting agent Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Dispersion Chemistry (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

RU2013155479/15A 2011-05-13 2012-05-11 Интраназальные фармацевтические дозированные формы, содержащие налоксон RU2587051C2 (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP11166076		2011-05-13
EP11166076.7		2011-05-13
PCT/EP2012/058792 WO2012156317A2 (en)	2011-05-13	2012-05-11	Intranasal pharmaceutical dosage forms comprising naloxone

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2016117731A Division RU2657441C1 (ru)	2011-05-13	2012-05-11	Интраназальные фармацевтические дозированные формы, содержащие налоксон

Publications (2)

Publication Number	Publication Date
RU2013155479A RU2013155479A (ru)	2015-06-20
RU2587051C2 true RU2587051C2 (ru)	2016-06-10

Family

ID=44658496

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
RU2016117731A RU2657441C1 (ru)	2011-05-13	2012-05-11	Интраназальные фармацевтические дозированные формы, содержащие налоксон
RU2013155479/15A RU2587051C2 (ru)	2011-05-13	2012-05-11	Интраназальные фармацевтические дозированные формы, содержащие налоксон

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
RU2016117731A RU2657441C1 (ru)	2011-05-13	2012-05-11	Интраназальные фармацевтические дозированные формы, содержащие налоксон

Country Status (36)

Country	Link
US (7)	US20150018379A1 (da)
EP (2)	EP2706982B2 (da)
JP (3)	JP6110367B2 (da)
KR (2)	KR101873174B1 (da)
CN (2)	CN107260672A (da)
AR (1)	AR086391A1 (da)
AT (1)	AT16553U1 (da)
AU (2)	AU2012257785B2 (da)
BR (1)	BR112013029126A2 (da)
CA (1)	CA2835940C (da)
CO (1)	CO6821959A2 (da)
CY (1)	CY1120399T1 (da)
DE (1)	DE202012013606U1 (da)
DK (2)	DK2706982T4 (da)
ES (1)	ES2661838T5 (da)
HK (1)	HK1255428A1 (da)
HR (1)	HRP20180233T1 (da)
HU (1)	HUE036465T2 (da)
IL (1)	IL229409B (da)
LT (1)	LT2706982T (da)
ME (1)	ME02958B (da)
MX (1)	MX354249B (da)
MY (1)	MY194947A (da)
NO (1)	NO2706982T3 (da)
PH (1)	PH12016501342B1 (da)
PL (1)	PL2706982T3 (da)
PT (1)	PT2706982T (da)
RS (1)	RS57054B1 (da)
RU (2)	RU2657441C1 (da)
SG (1)	SG194927A1 (da)
SI (1)	SI2706982T1 (da)
TR (1)	TR201802716T4 (da)
TW (1)	TWI486161B (da)
UA (1)	UA110974C2 (da)
WO (1)	WO2012156317A2 (da)
ZA (1)	ZA201308280B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8939943B2 (en)	2011-01-26	2015-01-27	Kaleo, Inc.	Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en)	2011-02-28	2014-01-14	Intelliject, Inc.	Medicament delivery device for administration of opioid antagonists including formulations for naloxone
ME02958B (me) *	2011-05-13	2018-07-20	Euro Celtique Sa	Intranazalni farmaceutski dozni oblici коji obuhvataju nalokson
CA2875384A1 (en)	2013-12-20	2015-06-20	AntiOP, Inc.	Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en)	2014-03-14	2018-10-02	Adapt Pharma Limited	Nasal drug products and methods of their use
US9561177B2 (en)	2014-03-14	2017-02-07	Adapt Pharma Limited	Nasal drug products and methods of their use
US9480644B2 (en)	2014-03-14	2016-11-01	Opiant Pharmaceuticals, Inc.	Nasal drug products and methods of their use
DE112015001251T5 (de)	2014-03-14	2017-01-19	Opiant Pharmaceuticals Inc.	Nasale Arzneimittelprodukte und Verfahren zu deren Verwendung
US10722510B2 (en)	2014-07-08	2020-07-28	Hikma Pharmaceuticals Usa Inc.	Liquid naloxone spray
US11135155B2 (en) *	2014-07-08	2021-10-05	Hikma Pharmaceuticals Usa Inc.	Liquid naloxone spray
WO2016007729A1 (en) *	2014-07-09	2016-01-14	Lightlake Therapeutics Inc.	Co-packaged drug products
US9517307B2 (en)	2014-07-18	2016-12-13	Kaleo, Inc.	Devices and methods for delivering opioid antagonists including formulations for naloxone
WO2017011326A1 (en) *	2015-07-10	2017-01-19	Sanjay Gupta	Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene
MX2018003349A (es) *	2015-09-17	2018-11-12	Adapt Pharma Ltd	Productos de farmaco nasal y metodos de su uso.
KR102634829B1 (ko) *	2016-06-24	2024-02-07	오피언트 파마슈티컬스, 인코퍼레이티드	알코올 사용 장애의 치료용 조성물, 장치 및 방법
JP7114570B2 (ja) *	2016-08-17	2022-08-08	ヒクマ・ファーマシューティカルズ・ユー・エス・エイ・インコーポレイテッド	液体ナロキソンスプレー
AU2020245535B2 (en) *	2019-03-26	2022-06-30	Pocket Naloxone Corp.	Devices and methods for delivering pharmaceutical compositions
EP3946547A4 (en)	2019-03-26	2023-01-18	Pocket Naloxone Corp.	DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS
US10729687B1 (en)	2019-07-09	2020-08-04	Orexo Ab	Pharmaceutical composition for nasal delivery
US10653690B1 (en) *	2019-07-09	2020-05-19	Orexo Ab	Pharmaceutical composition for nasal delivery
WO2021222545A1 (en) *	2020-04-29	2021-11-04	The Texas A&M University System	Naloxone nanoparticle compositions and methods thereof
MX2022014216A (es)	2020-05-18	2022-12-07	Orexo Ab	Nueva composicion farmaceutica para administracion de farmacos.
US11278709B1 (en)	2021-03-12	2022-03-22	Pocket Naloxone Corp.	Drug delivery device and methods for using same
KR20240103005A (ko)	2021-11-25	2024-07-03	오렉쏘 에이비	아드레날린을 포함하는 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2344822C2 (ru) *	2006-04-05	2009-01-27	Алексей Валентинович Надеждин	Способ лечения героиновой наркомании

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4464378A (en) *	1981-04-28	1984-08-07	University Of Kentucky Research Foundation	Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB9202464D0 (en)	1992-02-05	1992-03-18	Danbiosyst Uk	Composition for nasal administration
US5866154A (en) *	1994-10-07	1999-02-02	The Dupont Merck Pharmaceutical Company	Stabilized naloxone formulations
US6608073B1 (en)	1998-10-14	2003-08-19	New Millennium Pharmaceutical Research, Inc.	Intranasal codeine for the rapid suppression of cough and rapid relief of pain
GB9908921D0 (en) *	1999-04-19	1999-06-16	Britannia Pharmaceuticals Ltd	Spray dispenser for opiod antagonists
DE10084709T1 (de)	1999-06-16	2002-09-26	Nastech Pharm Co	Pharmazeutische Formulierung und Verfahren, die intranasales Morphin umfassen
GB9924797D0 (en)	1999-10-20	1999-12-22	West Pharm Serv Drug Res Ltd	Compound
US6284765B1 (en)	2000-04-27	2001-09-04	The University Of North Texas Health Science Center At Fort Worth	(+) naloxone and epinephrine combination therapy
WO2002011778A1 (en) *	2000-05-10	2002-02-14	University Of Kentucky Research Foundation	System and method for intranasal administration of opioids
US20040115133A1 (en) *	2000-05-10	2004-06-17	Wermeling Daniel P.	Intranasal opioid compositions
DE20122843U1 (de) *	2000-07-31	2008-06-26	Nycomed Danmark Aps	Fentanyl Zusammensetzung zur nasalen Anwendung
DE10064219B9 (de)	2000-12-22	2009-02-12	Nasalis Pain Relief International Gmbh	Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US7666876B2 (en)	2002-03-19	2010-02-23	Vernalis (R&D) Limited	Buprenorphine formulations for intranasal delivery
EP1535615A4 (en)	2002-07-11	2010-03-31	Taiho Pharmaceutical Co Ltd	COMPOSITION FOR THE NASAL ABSORPTION
GB0300531D0 (en)	2003-01-10	2003-02-12	West Pharm Serv Drug Res Ltd	Pharmaceutical compositions
CN1575795A (zh) *	2003-06-25	2005-02-09	中国人民解放军军事医学科学院毒物药物研究所	盐酸纳洛酮鼻腔喷雾剂
GB2403711A (en) *	2003-07-07	2005-01-12	Gw Pharma Ltd	Drug dispenser with controlled access
GB0400804D0 (en)	2004-01-14	2004-02-18	Innoscience Technology Bv	Pharmaceutical compositions
CN1726915B (zh) *	2004-07-27	2013-04-24	中国人民解放军军事医学科学院毒物药物研究所	盐酸纳洛酮鼻腔给药***或组合物及其制备方法
WO2006016530A1 (ja)	2004-08-10	2006-02-16	Translational Research, Ltd.	速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US20090040595A1 (en) *	2004-11-09	2009-02-12	Koninklijke Philips Electronics, N.V.	Array of spatial light modulators an dmethod of production of a spatial light modulator device
KR20070091682A (ko) *	2004-12-23	2007-09-11	록스로 파마 인코퍼레이티드	케토롤락의 비내 투여용 치료 조성물
US8911751B2 (en)	2005-10-11	2014-12-16	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Compositions for nasal delivery
US20070212307A1 (en) *	2006-02-10	2007-09-13	Daniel Wermeling	Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
WO2008078730A1 (ja)	2006-12-26	2008-07-03	Translational Research, Ltd.	経鼻投与用製剤
ES2611995T3 (es) *	2007-01-19	2017-05-11	Hananja Ehf	Métodos y composiciones para el suministro de un agente terapéutico
WO2009040595A1 (en)	2007-09-28	2009-04-02	Wockhardt Research Centre	Multi-dose pharmaceutical composition of analgesic for nasal administration
ME02958B (me) *	2011-05-13	2018-07-20	Euro Celtique Sa	Intranazalni farmaceutski dozni oblici коji obuhvataju nalokson
CA2875384A1 (en)	2013-12-20	2015-06-20	AntiOP, Inc.	Intranasal naloxone compositions and methods of making and using same
DE112015001251T5 (de)	2014-03-14	2017-01-19	Opiant Pharmaceuticals Inc.	Nasale Arzneimittelprodukte und Verfahren zu deren Verwendung
US10085937B2 (en)	2014-03-14	2018-10-02	Adapt Pharma Limited	Nasal drug products and methods of their use
US9561177B2 (en)	2014-03-14	2017-02-07	Adapt Pharma Limited	Nasal drug products and methods of their use
US9480644B2 (en)	2014-03-14	2016-11-01	Opiant Pharmaceuticals, Inc.	Nasal drug products and methods of their use
US10617686B2 (en)	2014-07-08	2020-04-14	Hikma Pharmaceuticals Usa Inc.	Liquid naloxone spray

2012
- 2012-05-11 ME MEP-2018-35A patent/ME02958B/me unknown
- 2012-05-11 RU RU2016117731A patent/RU2657441C1/ru active
- 2012-05-11 KR KR1020177001202A patent/KR101873174B1/ko active IP Right Grant
- 2012-05-11 SG SG2013083886A patent/SG194927A1/en unknown
- 2012-05-11 ES ES12721507T patent/ES2661838T5/es active Active
- 2012-05-11 CA CA2835940A patent/CA2835940C/en active Active
- 2012-05-11 WO PCT/EP2012/058792 patent/WO2012156317A2/en active Application Filing
- 2012-05-11 CN CN201710310253.2A patent/CN107260672A/zh active Pending
- 2012-05-11 MY MYPI2018001495A patent/MY194947A/en unknown
- 2012-05-11 MX MX2013013276A patent/MX354249B/es active IP Right Grant
- 2012-05-11 DE DE202012013606.2U patent/DE202012013606U1/de not_active Expired - Lifetime
- 2012-05-11 RU RU2013155479/15A patent/RU2587051C2/ru not_active IP Right Cessation
- 2012-05-11 DK DK12721507.7T patent/DK2706982T4/da active
- 2012-05-11 AT ATGM50043/2018U patent/AT16553U1/de not_active IP Right Cessation
- 2012-05-11 TR TR2018/02716T patent/TR201802716T4/tr unknown
- 2012-05-11 EP EP12721507.7A patent/EP2706982B2/en active Active
- 2012-05-11 NO NO12721507A patent/NO2706982T3/no unknown
- 2012-05-11 US US14/084,551 patent/US20150018379A1/en not_active Abandoned
- 2012-05-11 RS RS20180193A patent/RS57054B1/sr unknown
- 2012-05-11 AU AU2012257785A patent/AU2012257785B2/en active Active
- 2012-05-11 JP JP2014509762A patent/JP6110367B2/ja active Active
- 2012-05-11 PL PL12721507T patent/PL2706982T3/pl unknown
- 2012-05-11 TW TW101116857A patent/TWI486161B/zh not_active IP Right Cessation
- 2012-05-11 BR BR112013029126A patent/BR112013029126A2/pt not_active IP Right Cessation
- 2012-05-11 HU HUE12721507A patent/HUE036465T2/hu unknown
- 2012-05-11 AR ARP120101700A patent/AR086391A1/es unknown
- 2012-05-11 SI SI201231239T patent/SI2706982T1/en unknown
- 2012-05-11 CN CN201280032034.8A patent/CN103764119A/zh not_active Withdrawn
- 2012-05-11 KR KR1020137032730A patent/KR101698182B1/ko active IP Right Grant
- 2012-05-11 EP EP17208976.5A patent/EP3320893A1/en not_active Withdrawn
- 2012-05-11 LT LTEP12721507.7T patent/LT2706982T/lt unknown
- 2012-05-11 PT PT127215077T patent/PT2706982T/pt unknown
- 2012-11-05 UA UAA201314634A patent/UA110974C2/uk unknown
2013
- 2013-11-05 ZA ZA2013/08280A patent/ZA201308280B/en unknown
- 2013-11-12 IL IL229409A patent/IL229409B/en active IP Right Grant
- 2013-12-13 CO CO13291649A patent/CO6821959A2/es not_active Application Discontinuation
2015
- 2015-01-06 US US14/590,808 patent/US20150126540A1/en not_active Abandoned
2016
- 2016-01-14 JP JP2016005172A patent/JP2016128453A/ja active Pending
- 2016-07-05 PH PH12016501342A patent/PH12016501342B1/en unknown
- 2016-07-13 AU AU2016204880A patent/AU2016204880B2/en active Active
2017
- 2017-01-27 US US15/418,138 patent/US20170231904A1/en not_active Abandoned
- 2017-05-09 US US15/590,466 patent/US20170304192A1/en not_active Abandoned
2018
- 2018-02-07 HR HRP20180233TT patent/HRP20180233T1/hr unknown
- 2018-02-26 CY CY20181100228T patent/CY1120399T1/el unknown
- 2018-04-19 DK DKBA201800034U patent/DK201800034U1/da not_active Application Discontinuation
- 2018-05-09 JP JP2018090275A patent/JP2018150336A/ja active Pending
- 2018-11-15 HK HK18114591.4A patent/HK1255428A1/zh unknown
2019
- 2019-08-23 US US16/549,838 patent/US11020343B2/en active Active
2021
- 2021-04-23 US US17/238,509 patent/US11806428B2/en active Active
2023
- 2023-09-19 US US18/370,116 patent/US20240082149A1/en active Pending

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2344822C2 (ru) *	2006-04-05	2009-01-27	Алексей Валентинович Надеждин	Способ лечения героиновой наркомании

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
НАДЕЖДИН А.В. и др., Возможность применения низких доз налоксона при лечении героиновой наркомании.-Журнал неврологии и психиатрии им.С.С.Корсакова,2006,т.106, N1, стр.56-57. KERR D. et al., Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose, ADDICTION, Research Report, vol.104, 2009, p.2067-2074. *

Also Published As

Publication number	Publication date
JP2014513683A (ja)	2014-06-05
RS57054B1 (sr)	2018-05-31
DE202012013606U1 (de)	2018-04-18
CO6821959A2 (es)	2013-12-31
EP2706982B2 (en)	2021-03-10
NO2706982T3 (da)	2018-06-02
BR112013029126A2 (pt)	2017-02-07
KR101873174B1 (ko)	2018-06-29
AU2012257785A1 (en)	2013-11-28
EP2706982A2 (en)	2014-03-19
US20170231904A1 (en)	2017-08-17
AU2016204880A1 (en)	2016-07-28
ME02958B (me)	2018-07-20
PL2706982T3 (pl)	2018-07-31
NZ705933A (en)	2016-07-29
EP3320893A1 (en)	2018-05-16
IL229409A0 (en)	2014-01-30
SG194927A1 (en)	2013-12-30
CA2835940A1 (en)	2012-11-22
PH12016501342A1 (en)	2018-06-11
EP2706982B1 (en)	2018-01-03
WO2012156317A2 (en)	2012-11-22
TW201311244A (zh)	2013-03-16
JP2018150336A (ja)	2018-09-27
TWI486161B (zh)	2015-06-01
KR20170010078A (ko)	2017-01-25
US20150018379A1 (en)	2015-01-15
KR20140007482A (ko)	2014-01-17
RU2657441C1 (ru)	2018-06-13
TR201802716T4 (tr)	2018-03-21
HK1255428A1 (zh)	2019-08-16
DK2706982T4 (da)	2021-05-10
IL229409B (en)	2020-10-29
MY194947A (en)	2022-12-27
NZ617442A (en)	2015-03-27
US20210338574A1 (en)	2021-11-04
CN107260672A (zh)	2017-10-20
RU2013155479A (ru)	2015-06-20
JP2016128453A (ja)	2016-07-14
DK201800034U1 (da)	2018-05-25
US20190374464A1 (en)	2019-12-12
US11020343B2 (en)	2021-06-01
MX2013013276A (es)	2014-08-07
MX354249B (es)	2018-02-20
ES2661838T5 (es)	2021-11-18
CY1120399T1 (el)	2019-07-10
US20150126540A1 (en)	2015-05-07
AU2012257785B2 (en)	2016-04-14
JP6110367B2 (ja)	2017-04-05
PH12016501342B1 (en)	2018-06-11
ZA201308280B (en)	2014-07-30
CA2835940C (en)	2020-08-04
CN103764119A (zh)	2014-04-30
AT16553U1 (de)	2020-01-15
PT2706982T (pt)	2018-03-08
ES2661838T3 (es)	2018-04-04
HRP20180233T1 (hr)	2018-06-01
SI2706982T1 (en)	2018-05-31
US20240082149A1 (en)	2024-03-14
US20170304192A1 (en)	2017-10-26
US11806428B2 (en)	2023-11-07
LT2706982T (lt)	2018-05-25
UA110974C2 (uk)	2016-03-10
DK2706982T3 (da)	2018-03-12
WO2012156317A3 (en)	2013-05-10
AR086391A1 (es)	2013-12-11
AU2016204880B2 (en)	2017-11-23
KR101698182B1 (ko)	2017-01-19
HUE036465T2 (hu)	2018-07-30

Legal Events

Date	Code	Title	Description
2021-02-11	MM4A	The patent is invalid due to non-payment of fees	Effective date: 20200512

Publication	Publication Date	Title
RU2587051C2 (ru)	2016-06-10	Интраназальные фармацевтические дозированные формы, содержащие налоксон
JP2007503448A (ja)	2007-02-22	鼻内オピオイド組成物
JP2010520186A (ja)	2010-06-10	医薬組成物における改善および医薬組成物に関する改善
CA2464261A1 (en)	2003-05-01	Apomorphine-containing dosage form for ameliorating male erectile dysfunction
KR20200022026A (ko)	2020-03-02	치료 방법 및 이의 약형
NZ705933B2 (en)	2016-11-01	Intranasal pharmaceutical dosage forms comprising naloxone
NZ617442B2 (en)	2015-06-30	Intranasal pharmaceutical dosage forms comprising naloxone